Quarterly ResultApr 30, 2026, 04:03 PM
SNDX Q1 Revenue +224% to $64.9M; Revuforj $48.9M; Niktimvo $15.9M
AI Summary
Syndax Pharmaceuticals reported strong first-quarter 2026 financial results, with total revenue increasing 224% year-over-year to $64.9 million. This growth was driven by Revuforj net revenue of $48.9 million and Niktimvo collaboration revenue of $15.9 million. The company also anticipates multiple key pipeline catalysts, including new revumenib data in Q2 2026 and topline data from Phase 2 axatilimab trials in IPF and chronic GVHD in Q4 2026, positioning the company for continued commercial growth and profitability.
Key Highlights
- Total revenue increased 224% year-over-year to $64.9 million in Q1 2026.
- Revuforj net revenue reached $48.9 million, up 144% YoY and 11% QoQ.
- Niktimvo collaboration revenue was $15.9 million from $55.1 million net sales.
- Revuforj total prescriptions increased by approximately 160% compared to Q1 2025.
- New revumenib real-world, frontline, and post-HSCT maintenance data expected in Q2 2026.
- Topline data from Phase 2 axatilimab trials in IPF and chronic GVHD expected in Q4 2026.
- Cash, cash equivalents, and short-term investments totaled $352.1 million as of March 31, 2026.
- Q1 2026 R&D expenses decreased to $58.8 million from $61.6 million year-over-year.